Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Biallelic tumor suppressor loss and DNA repair defects in de novo small cell prostate cancer.

Chedgy EC, Vandekerkhove G, Herberts C, Annala M, Donoghue AJ, Sigouros M, Ritch E, Struss W, Konomura S, Liew J, Parimi S, Vergidis J, Hurtado-Coll A, Sboner A, Fazli L, Beltran H, Chi KN, Wyatt AW.

J Pathol. 2018 Jul 17. doi: 10.1002/path.5137. [Epub ahead of print]

PMID:
30015382
2.

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN.

Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24.

PMID:
29367197
3.

Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.

Kalina JL, Neilson DS, Comber AP, Rauw JM, Alexander AS, Vergidis J, Lum JJ.

Cancers (Basel). 2017 Jan 27;9(2). pii: E13. doi: 10.3390/cancers9020013. Review.

4.

Impact of Weight Changes After the Diagnosis of Stage III Colon Cancer on Survival Outcomes.

Vergidis J, Gresham G, Lim HJ, Renouf DJ, Kennecke HF, Ruan JY, Chang JT, Cheung WY.

Clin Colorectal Cancer. 2016 Mar;15(1):16-23. doi: 10.1016/j.clcc.2015.07.002. Epub 2015 Jul 26.

PMID:
26281943
5.

Cost-effectiveness of therapies for melanoma.

Johnston KM, McPherson E, Osenenko K, Vergidis J, Levy AR, Peacock S.

Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):229-42. doi: 10.1586/14737167.2015.1017563. Epub 2015 Feb 23. Review.

PMID:
25703441
6.

KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.

Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, Fahim S, Keating A.

Exp Hematol. 2005 Oct;33(10):1160-71.

PMID:
16219538

Supplemental Content

Loading ...
Support Center